Actos (Pioglitazone) Cost in Nevada 2026

What Does Pioglitazone Actually Cost in Nevada?

Generic pioglitazone is one of the more affordable oral diabetes agents available in Nevada in 2026. At major retail chains including Walgreens, CVS, and Smith's Food and Drug (a Kroger banner), the average cash price sits near $15 per month for a 30-tablet supply of 30 mg tablets. Brand-name Actos, still manufactured by Takeda, carries a published wholesale acquisition cost closer to $60 per month for the same supply, though very few cash-paying patients purchase the brand at that price.

The FDA approved pioglitazone as a thiazolidinedione (TZD) insulin sensitizer for type 2 diabetes mellitus as an adjunct to diet and exercise. The current prescribing information is maintained in the FDA's Drugs@FDA database.

Retail Price Breakdown by Dose

Pioglitazone is sold in 15 mg, 30 mg, and 45 mg tablets. Prices at Nevada pharmacies in 2026 vary modestly by strength:

• 15 mg, 30 tablets: approximately $12, $16 cash
• 30 mg, 30 tablets: approximately $14, $18 cash
• 45 mg, 30 tablets: approximately $15, $20 cash

The 45 mg strength is often only a dollar or two more than the 15 mg strength, so patients titrated to the highest dose do not face a steep additional cost. The American Diabetes Association's 2024 Standards of Care recommend pioglitazone as a cost-effective agent in patients with insulin resistance or nonalcoholic fatty liver disease.

How GoodRx and Coupon Programs Work in Nevada

Coupon aggregators such as GoodRx and RxSaver negotiate contracted rates with pharmacy benefit managers. In Nevada, applying a GoodRx coupon at Walgreens or CVS typically drops the 30 mg, 30-tablet price to $10, $13. These coupons cannot be combined with insurance or Medicaid. The coupon is free to obtain and requires no membership.

A 2021 analysis in JAMA Internal Medicine found that GoodRx prices were lower than insurance copays for a subset of generic drugs, including common diabetes medications.

Patients paying cash should compare the coupon price against the pharmacy's own generic program price. Walmart's $4 generic list and Costco's member pricing in Nevada can sometimes match or beat coupon aggregator rates.

Does Nevada Medicaid Cover Pioglitazone?

Nevada Medicaid (Nevada Check Up and Nevada Medicaid) does not routinely include pioglitazone on its preferred drug list (PDL) for type 2 diabetes mellitus as of 2026. The Nevada Division of Health Care Financing and Policy maintains a PDL that favors metformin as first-line therapy and GLP-1 receptor agonists in select high-risk cardiovascular populations.

Prior Authorization Pathway

Pioglitazone is not categorically excluded from Nevada Medicaid. A prescriber may submit a prior authorization (PA) request documenting:

1. Failure of or contraindication to preferred agents (metformin, a sulfonylurea)
2. A clinical indication such as documented insulin resistance or biopsy-confirmed NASH
3. The expected duration of therapy

PA approval is granted on a case-by-case basis. Approval rates are not publicly published by the Nevada Division of Health Care Financing. The Endocrine Society's 2023 clinical practice guideline on diabetes pharmacotherapy notes that TZDs retain a role in patients with concurrent fatty liver disease or in whom hypoglycemia risk must be minimized.

NASH and Off-Label Medicaid Coverage

The PIVENS trial (N=247) published in the New England Journal of Medicine in 2010 demonstrated that pioglitazone 30 mg daily produced histological improvement in NASH in 34% of participants versus 19% on placebo (P<0.04). Read the PIVENS primary results at PubMed. Nevada Medicaid does not have a published coverage policy for pioglitazone in NASH, and off-label PA requests for this indication face a higher documentation burden.

How Pioglitazone Is Covered by Private Insurance in Nevada

Private insurance coverage for generic pioglitazone in Nevada is generally favorable. Most commercial plans place it on Tier 1 or Tier 2 of the formulary, resulting in copays between $0 and $20 per month for members.

Major Payer Formulary Tiers in Nevada

Nevada's largest commercial insurers include Anthem Blue Cross Blue Shield, UnitedHealthcare, Aetna, and Cigna. Formulary placement for generic pioglitazone in 2026:

• Anthem BCBS Nevada: Tier 1 on most individual and group plans, $0, $10 copay
• UnitedHealthcare Nevada: Tier 1 generic, $5, $15 copay depending on plan design
• Aetna Nevada: Tier 2 on some HDHP designs, $10, $25 copay
• Cigna Nevada: Tier 1 on most plans, $0, $10 copay

The Academy of Managed Care Pharmacy framework for formulary management recommends placing cost-effective generics on Tier 1 to reduce adherence barriers.

Brand Actos is placed on Tier 3 or non-preferred brand status by virtually all Nevada commercial plans, producing copays of $50, $100 per month or higher, depending on whether the member has met their deductible.

Employer Self-Insured Plans

Nevada employers with self-insured benefit plans (governed by ERISA rather than state insurance law) may use national formulary templates provided by their pharmacy benefit manager. In practice, these almost always include generic pioglitazone on Tier 1. Employees at large Nevada employers such as MGM Resorts International, Caesars Entertainment, or the state of Nevada itself should verify tier placement through their plan's online drug lookup tool before assuming coverage.

The ADA's 2024 Standards of Care Section 9 advises clinicians to consider formulary placement when selecting glucose-lowering agents.

Medicare Part D in Nevada

Medicare Part D plans in Nevada vary significantly in formulary design. In 2026, most Part D plans include generic pioglitazone. The Low Income Subsidy (Extra Help) program reduces the copay to $0, $4 for qualifying beneficiaries. Patients with Medicare Advantage plans should check their plan's formulary through the Medicare Plan Finder at medicare.gov.

Is Compounded Pioglitazone Legal in Nevada?

Yes. Nevada permits 503A compounding pharmacies to prepare pioglitazone compounds for individual patients when a valid prescription is presented from a licensed prescriber. FDA regulations governing 503A pharmacies, including what may and may not be compounded, are outlined in 21 U.S.C. 353a.

What 503A Means for Nevada Patients

A 503A pharmacy compounds medications for specific patients based on individual prescriptions. This is distinct from 503B outsourcing facilities, which produce large batches for hospital or office use. In Nevada, several independent compounding pharmacies hold 503A status and can compound pioglitazone into alternative formulations (for example, a capsule strength not commercially available, or a topical or oral suspension for patients with swallowing difficulties).

The Nevada State Board of Pharmacy maintains a list of licensed compounding pharmacies at pharmacy.nv.gov.

Cost for compounded pioglitazone through a 503A pharmacy in Nevada varies widely. Some telehealth and clinical programs include compounded pioglitazone as part of a broader metabolic treatment protocol at little or no additional charge to the patient. Outside of those programs, compounded pioglitazone costs $20, $50 per month depending on the formulation and dispensing pharmacy.

Clinical Rationale for Compounded Formulations

Most patients prescribed pioglitazone for type 2 diabetes or NASH will do fine with the commercially available 15 mg, 30 mg, or 45 mg tablets. Compounded formulations become clinically relevant in specific situations:

• Patients requiring a dose outside the standard range (for example, 7.5 mg for tolerability in NASH protocols)
• Pediatric off-label use requiring weight-based dosing in a liquid formulation
• Combination capsules that simplify a multi-drug regimen

A 2019 review in Hepatology found that pioglitazone doses as low as 15 to 30 mg daily produced significant reductions in ALT and hepatic fat fraction in NASH patients.

Can Nevada Patients Get Pioglitazone via Telehealth?

Telehealth prescribing of pioglitazone is legal in Nevada. The Nevada Telehealth Act (NRS 629.515 et seq.) allows licensed Nevada physicians, nurse practitioners, and physician assistants to evaluate patients and prescribe Schedule-uncontrolled medications, including pioglitazone, via synchronous audio-video visits.

Nevada Telehealth Prescribing Rules

Pioglitazone is not a controlled substance under federal or Nevada law, so no in-person visit is required prior to prescribing via telehealth. The prescriber must:

1. Establish a valid patient-provider relationship through a synchronous visit
2. Review relevant labs (HbA1c, fasting glucose, liver function tests, and a baseline assessment for edema and heart failure risk)
3. Transmit the prescription electronically to a Nevada-licensed pharmacy

The Nevada State Board of Medical Examiners provides telehealth guidance aligned with the Federation of State Medical Boards' Model Policy.

What Labs Should Be Reviewed Before Starting

The FDA prescribing information for pioglitazone requires assessment of fluid retention risk and liver function before initiation. Specifically, pioglitazone is contraindicated in NYHA Class III or IV heart failure. The full FDA prescribing label is available at Drugs@FDA. A baseline HbA1c, comprehensive metabolic panel, and echocardiogram (if cardiac history is present) are standard pre-treatment workup steps at HealthRX.

The American Heart Association's 2022 scientific statement on diabetes and cardiovascular risk specifically notes that TZDs increase fluid retention risk and should be avoided in patients with symptomatic heart failure.

What the Clinical Evidence Says About Pioglitazone

Pioglitazone's evidence base is substantial. Two areas receive the most clinical attention: glycemic control in type 2 diabetes and histological benefit in NASH.

Type 2 Diabetes: Glycemic and Cardiovascular Data

The PROactive trial (N=5,238) randomized patients with type 2 diabetes and macrovascular disease to pioglitazone 45 mg daily versus placebo. The primary composite endpoint (all-cause mortality, nonfatal MI, stroke, ACS, leg amputation, coronary revascularization, or leg revascularization) did not reach statistical significance (hazard ratio 0.90, 95% CI 0.80 to 1.02, P<0.095). PROactive primary results at PubMed. The secondary main endpoint (all-cause mortality, nonfatal MI, and stroke) did reach significance (HR 0.84, P<0.027), making PROactive evidence of cardiovascular signal rather than definitive benefit.

The American Diabetes Association's 2024 Standards of Care rate pioglitazone as an acceptable second-line agent when cost and hypoglycemia avoidance are priorities.

NASH: The PIVENS Trial

In the PIVENS trial (N=247), adults with biopsy-confirmed NASH were randomized to pioglitazone 30 mg daily, vitamin E 800 IU daily, or placebo for 96 weeks. Pioglitazone reduced hepatocyte ballooning score and produced a 2-point or greater reduction in the NAFLD Activity Score in 34% of participants versus 19% on placebo. Full PIVENS results: PubMed PMID 20427778.

The American Association for the Study of Liver Diseases (AASLD) 2023 Practice Guidance on MAFLD includes pioglitazone as a recommended pharmacologic option for biopsy-confirmed NASH with fibrosis stage F2 or higher.

Bone Fracture and Bladder Cancer Risk

Two safety signals require disclosure to Nevada patients:

1. Pioglitazone increases fracture risk in women, particularly distal limb fractures. A meta-analysis in Diabetes Care (2010) found an odds ratio of 1.94 for fractures in women taking TZDs.
2. Long-term pioglitazone use (over 24 months) was associated with a modest increase in bladder cancer risk in the FDA's 2011 safety communication. FDA bladder cancer safety communication, 2011. That risk estimate (HR approximately 1.4 for use over 24 months) has been debated in subsequent analyses, but the FDA label retains a warning.

Nevada-Specific Cost-Reduction Strategies

The table below organizes cost-reduction options by payer status for Nevada patients in 2026. Choose the row that matches your current coverage.

| Patient Situation | Best Option | Estimated Monthly Cost | |---|---|---| | Uninsured, cash-pay | GoodRx coupon at Walgreens or CVS | $10, $13 | | Uninsured, prefers generic program | Walmart $4 generic list | $4, $10 | | Commercial insurance, Tier 1 | Use insurance, no coupon | $0, $15 | | Commercial insurance, brand Actos only | Request generic substitution from prescriber | $0, $15 | | Nevada Medicaid, PA denied | Appeal or seek 340B-eligible clinic | $0, $5 | | Medicare Part D, Extra Help | Low Income Subsidy copay | $0, $4 | | Telehealth patient, NASH protocol | 503A compounding pharmacy | $0, $50 | | Uninsured, income-eligible | NeedyMeds.org patient assistance programs | $0 |

Takeda Patient Assistance Program

Takeda offers a patient assistance program (Takeda Patient Assistance Program, TAP) for brand Actos. Eligibility requires income at or below 600% of the federal poverty level and no Medicare Part D coverage. Nevada residents apply through needymeds.org or directly at takedahelp.com. Approval typically takes 2 to 4 weeks.

NeedyMeds.org maintains an up-to-date database of patient assistance programs for brand and generic medications.

340B Drug Pricing for Nevada Clinics

Nevada has multiple federally qualified health centers (FQHCs) that participate in the 340B drug pricing program. At 340B-eligible sites, pioglitazone may be dispensed to qualifying patients at a price significantly below the retail cash price, sometimes under $5 per month. The Health Resources and Services Administration (HRSA) maintains the 340B program database. Nevada FQHCs include Community Health Alliance (Reno), Nevada Health Centers (Carson City, Elko, Fallon), and Homeless Healthcare of Las Vegas.

Monitoring Pioglitazone in Nevada Patients

Starting pioglitazone requires a baseline workup and ongoing monitoring. Prescribers in Nevada, whether in-person or telehealth, should follow these intervals:

• HbA1c: every 3 months until stable, then every 6 months
• Liver function tests: baseline, then annually (or if symptoms develop)
• Weight and edema assessment: every visit
• Bladder symptoms: ask at every annual review; hematuria warrants urology referral
• Bone density (DXA): baseline in postmenopausal women, then every 2 years

The Endocrine Society's 2023 guideline on diabetes pharmacotherapy includes TZD-specific monitoring recommendations consistent with the above schedule.

The FDA-approved pioglitazone prescribing information specifies that liver function testing should be performed if symptoms suggestive of hepatic dysfunction develop.

A baseline echocardiogram is not required by label for all patients but should be obtained in any Nevada patient with a prior history of heart failure, reduced ejection fraction, or significant peripheral edema before pioglitazone is started. The drug is contraindicated in NYHA Class III or IV heart failure. The American Heart Association's position on TZDs and heart failure is detailed in its 2022 cardiovascular-diabetes scientific statement.

Pioglitazone Dosing and Titration Guide

The standard starting dose for type 2 diabetes is 15 to 30 mg once daily with or without food. Dose may be increased to 45 mg once daily after 8 to 12 weeks if glycemic targets are not met and the drug is tolerated. For NASH (off-label, per PIVENS protocol), 30 mg daily is the most studied dose.

The FDA prescribing label for pioglitazone specifies a maximum dose of 45 mg daily as monotherapy and notes that combination with insulin requires dose adjustment of insulin to reduce hypoglycemia risk.

A 2020 systematic review in Diabetes, Obesity and Metabolism found that pioglitazone 45 mg daily reduced HbA1c by a mean of 0.9 to 1.2 percentage points versus placebo across 12 trials.